Synthetic LH-releasing factor
Synthetic LH-releasing factor - General Information
Synthetic LH-releasing factor is another name for gonadotropin-releasing hormone (GnRH). It is a synthetic decapeptide prepared using solid phase peptide synthesis. GnRH is responsible for the release of follicle stimulating hormone and leutinizing hormone from the anterior pitutitary.
Pharmacology of Synthetic LH-releasing factor
Synthetic LH-releasing factor is responsible for the release of follicle stimulating hormone and leutinizing hormone from the anterior pitutitary. In the pituitary GnRH stimulates synthesis and release of FSH and LH, a process that is controlled by the frequency and amplitude of GnRH pulses, as well as the feedback of androgens and estrogens. The pulsatility of GnRH secretion has been seen in all vertebrates, and it is necessary to ensure a correct reproductive function. Thus a single hormone, GnRH, controls a complex process of follicular growth, ovulation, and corpus luteum maintenance in the female, and spermatogenesis in the male. Its short half life requires infusion pumps for its clinical use
Synthetic LH-releasing factor for patients
Synthetic LH-releasing factor Interactions
The Factrel test should be conducted in the absence of other drugs which directly affect the pituitary secretion of the gonadotropins. These would include a variety of preparations which contain androgens, estrogens, progestins, or glucocorticoids. The gonadotropin levels may be transiently elevated by spironolactone, minimally elevated by levodopa, and suppressed by oral contraceptives and digoxin. The response to Factrel may be blunted by phenothiazines and dopamine antagonists which cause a rise in prolactin.
Synthetic LH-releasing factor Contraindications
Hypersensitivity to gonadorelin hydrochloride or any of the components.
Additional information about Synthetic LH-releasing factor
Synthetic LH-releasing factor Indication: For evaluating the functional capacity and response of the gonadotropes of the anterior pituitary also for evaluating residual gonadotropic function of the pituitary following removal of a pituitary tumor by surgery and/or irradiation.
Mechanism Of Action: Systemic - Like naturally occurring gonadotropin-releasing hormone (GnRH), gonadorelin primarily stimulates the synthesis and release of luteinizing hormone (LH) from the anterior pituitary gland. Follicle-stimulating hormone (FSH) production and release is also increased by gonadorelin, but to a lesser degree. In prepubertal females and some gonadal function disorders, the FSH response may be greater than the LH response. For the treatment of amenorrhea, delayed puberty, and infertility the administration of gonadorelin is used to simulate the physiologic release of GnRH from the hypothalamus in treatment of delayed puberty, treatment of infertility caused by hypogonadotropic hypogonadism, and induction of ovulation in those women with hypothalamic amenorrhea. This results in increased levels of pituitary gonadotropins LH and FSH, which subsequently stimulate the gonads to produce reproductive steroids.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Gonadorelin
Synonyms: Not Available
Drug Category: Fertility Agents, Female
Drug Type: Small Molecule; Approved
Other Brand Names containing Gonadorelin: Dirigestran; Dirigestran Spofa; Factrel; Fertagyl; Gonadorelina [INN-Spanish]; Gonadorelinum [INN-Latin]; Gonadotropin releasing hormone; Gonadotropin-releasing factor; Gonadotropin-releasing hormone; Human LH-RH; Hypocrine; Luforan; Lutal; Lutamin; Lutrefact; Lutrepulse; Lutrepulse KIT; Mammalian GnRH; Mammalian LH-RH; Ovine LH-RH; Porchine LH-RH; Porcine LH-releasing factor; Relefact; Relisorm; Relisorm L; Synthetic Gn-RH; Synthetic LH-FSH releasing hormone; Synthetic LH-RF; Synthetic LH-RH; Synthetic LH-releasing factor; Synthetic LH-releasing hormone; Synthetic LRF; Synthetic decapeptide FSH/LH-RH; Synthetic gonadoliberin;
Absorption: Rapidly absorbed when injected
Toxicity (Overdose): LD50 >3000 mg/kg (rat, oral)
Protein Binding: Not Available
Biotransformation: Rapidly hydrolyzed to inactive peptide components
Half Life: Very short, initial, 2 to 10 minutes; terminal, 10 to 40 minutes
Dosage Forms of Synthetic LH-releasing factor: Powder, for solution Intravenous
Chemical IUPAC Name: N-[1-[[1-[[1-[[1-[[2-[[1-[[1-[2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(3H-imidazol-4-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
Chemical Formula: C55H75N17O13
Gonadorelin on Wikipedia: https://en.wikipedia.org/wiki/Gonadorelin
Organisms Affected: Humans and other mammals
